Orthobiologics & Regenerative Medicine Series: U.S. Marketplace for Unlicensed and Unproved Stem Cell Interventions presented by Leigh Turner, PhD-U.S. Marketplace for Unlicensed and Unproved Stem Cell Interventions

Video Transcription

Video Summary

The video features Dr. Turner discussing the proliferation of businesses and clinics in the United States that market stem cell interventions. These businesses often make misleading claims about the safety and efficacy of their products. Dr. Turner highlights that these interventions are often unproven and lack FDA approval. He expresses concern about the ethical issues associated with deceptive marketing claims and the impact on informed consent. Dr. Turner emphasizes the need for increased scrutiny and regulation in the field of regenerative medicine.<br /><br />The video transcript explores the challenges of informed consent in the field of stem cell interventions. It discusses how misleading claims and misinformation in the marketplace make it difficult for individuals and populations to differentiate between evidence-based interventions and unproven products. The speaker highlights the risks people face when making health and financial decisions based on misleading advertising.<br /><br />The impact of the COVID-19 pandemic on the stem cell market is also discussed, with some businesses claiming to have stem cell treatments for the virus. The importance of reliable safety and efficacy data, credible research, and clinical trials is emphasized. The video explores various responses to these challenges, including guidelines from the International Society for Stem Cell Research, government regulatory actions, civil litigation, and the importance of proper professional training. The need for transparency and accountability in the stem cell industry is highlighted, and the speaker suggests multiple layers of oversight are necessary to protect patient safety and promote credible research.

Keywords

stem cell interventions

misleading claims

safety and efficacy

FDA approval

ethical issues

informed consent

increased scrutiny

regulation

challenges of informed consent

reliable safety and efficacy data